Literature DB >> 8185325

Differential processing and secretion of the melanoma-associated ME20 antigen.

G A Maresh1, W C Wang, K S Beam, A R Malacko, I Hellström, K E Hellström, H Marquardt.   

Abstract

A murine monoclonal antibody, ME20, with high selectivity for melanomas, has been utilized to isolate a unique membrane-bound (designated ME20-M) and secreted (designated ME20-S) antigen from H3606 human melanoma cells. ME20-M was purified from the cell lysate and ME20-S from the conditioned medium of H3606 cells by immunoaffinity chromatography and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The apparent molecular weights were 105,000 and 76,000, respectively. Analyses of ME20-M and ME20-S by amino acid sequencing identified the processing sites. Signal peptide cleavage occurs at Thr-24 of pro-ME20 antigen, yielding ME20-M (25 to 661). In addition, proteolytic processing of the precursor at Val-467 yields ME20-S (25 to 467). We report the characterization of Asn-linked glycosylation sites in ME20-M and ME20-S to determine the involvement of oligosaccharides in the proteolytic processing of pro-ME20 antigen. Tryptic peptide maps of ME20-M and ME20-S were prepared and the glycosylation sites identified by sequence analyses. Oligosaccharides were enzymatically released and characterized by high-performance anion-exchange chromatography. We found high-mannose-type structures at Asn-57, Asn-82, and Asn-87 of ME20-M, whereas ME20-S contained 73% complex-type and 27% high-mannose-type oligosaccharides at the same sites. To assess the role of oligosaccharides in the processing of the ME20 antigen, we tested the effect of the oligosaccharide processing modifier deoxymannojirimycin, a compound that inhibits synthesis of hybrid- and complex-type oligosaccharides. Deoxymannojirimycin had no effect on the synthesis and relative rate of synthesis of ME20-M, but markedly reduced the synthesis of ME20-S without affecting the rate of secretion. The reported results suggest that carbohydrate maturation of the ME20 antigen may be important for processing and secretion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8185325     DOI: 10.1006/abbi.1994.1213

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  17 in total

1.  Pmel17 initiates premelanosome morphogenesis within multivesicular bodies.

Authors:  J F Berson; D C Harper; D Tenza; G Raposo; M S Marks
Journal:  Mol Biol Cell       Date:  2001-11       Impact factor: 4.138

2.  Premelanosome amyloid-like fibrils are composed of only golgi-processed forms of Pmel17 that have been proteolytically processed in endosomes.

Authors:  Dawn C Harper; Alexander C Theos; Kathryn E Herman; Danièle Tenza; Graça Raposo; Michael S Marks
Journal:  J Biol Chem       Date:  2007-11-08       Impact factor: 5.157

3.  Sorting of Pmel17 to melanosomes through the plasma membrane by AP1 and AP2: evidence for the polarized nature of melanocytes.

Authors:  Julio C Valencia; Hidenori Watabe; An Chi; Francois Rouzaud; Kevin G Chen; Wilfred D Vieira; Kaoruko Takahashi; Yuji Yamaguchi; Werner Berens; Kunio Nagashima; Jeffrey Shabanowitz; Donald F Hunt; Ettore Appella; Vincent J Hearing
Journal:  J Cell Sci       Date:  2006-02-21       Impact factor: 5.285

4.  Formation of Pmel17 amyloid is regulated by juxtamembrane metalloproteinase cleavage, and the resulting C-terminal fragment is a substrate for gamma-secretase.

Authors:  Markus P Kummer; Hiroko Maruyama; Claudia Huelsmann; Sandra Baches; Sascha Weggen; Edward H Koo
Journal:  J Biol Chem       Date:  2008-12-01       Impact factor: 5.157

5.  The repeat domain of the melanosome fibril protein Pmel17 forms the amyloid core promoting melanin synthesis.

Authors:  Ryan P McGlinchey; Frank Shewmaker; Peter McPhie; Begoña Monterroso; Kent Thurber; Reed B Wickner
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-31       Impact factor: 11.205

6.  Non-Synonymous variants in premelanosome protein (PMEL) cause ocular pigment dispersion and pigmentary glaucoma.

Authors:  Adrian A Lahola-Chomiak; Tim Footz; Kim Nguyen-Phuoc; Gavin J Neil; Baojian Fan; Keri F Allen; David S Greenfield; Richard K Parrish; Kevin Linkroum; Louis R Pasquale; Ralf M Leonhardt; Robert Ritch; Shari Javadiyan; Jamie E Craig; W T Allison; Ordan J Lehmann; Michael A Walter; Janey L Wiggs
Journal:  Hum Mol Genet       Date:  2019-04-15       Impact factor: 6.150

7.  The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding.

Authors:  Toshihiko Hoashi; Kunihiko Tamaki; Vincent J Hearing
Journal:  FASEB J       Date:  2009-11-02       Impact factor: 5.191

Review 8.  PMEL: a pigment cell-specific model for functional amyloid formation.

Authors:  Brenda Watt; Guillaume van Niel; Graça Raposo; Michael S Marks
Journal:  Pigment Cell Melanoma Res       Date:  2013-02-19       Impact factor: 4.693

9.  The PKD domain distinguishes the trafficking and amyloidogenic properties of the pigment cell protein PMEL and its homologue GPNMB.

Authors:  Alexander C Theos; Brenda Watt; Dawn C Harper; Karolina J Janczura; Sarah C Theos; Kathryn E Herman; Michael S Marks
Journal:  Pigment Cell Melanoma Res       Date:  2013-04-02       Impact factor: 4.693

10.  Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein.

Authors:  Toshihiko Hoashi; Shinichi Sato; Yuji Yamaguchi; Thierry Passeron; Kunihiko Tamaki; Vincent J Hearing
Journal:  FASEB J       Date:  2010-01-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.